Enlivex Therapeutics (ENLV) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
This Phase IIb study, titled “A Phase IIb, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis,” aims to see if Enlivex Therapeutics’ Allocetra can safely reduce pain and improve function in moderate to severe knee osteoarthritis. The trial’s outcome could guide Allocetra’s path toward larger late-stage studies and shape expectations for Enlivex’s long-term value.
The study tests intra-articular, or into-the-joint, injections of Allocetra, a cell-based drug designed to reset harmful immune activity in the knee joint. A placebo solution with the same ingredients but without Allocetra cells is used as the control to clearly measure any added benefit from the active treatment.
The trial is an interventional study in which patients are randomly assigned to either Allocetra or placebo, and both groups are treated in parallel over the same period. It uses triple blinding, meaning patients, doctors, and outcome assessors do not know who gets which treatment, and the main goal is to treat symptoms and measure pain and function changes as clearly as possible.
Enlivex first submitted the study in April 2026, marking the official start of its regulatory path. The latest update was filed on May 17, 2026, showing the trial is active and still recruiting, with primary and final completion dates to be confirmed as enrollment and follow-up progress.
For investors, this update confirms Enlivex is advancing Allocetra into mid-stage testing in knee osteoarthritis, a large market where many patients seek better options beyond painkillers and surgery. Positive signals from this trial could lift sentiment and support ENLV’s valuation, while mixed or negative data may weigh on the stock, especially given competition from established arthritis drugs and emerging cell and gene therapies.
The study remains ongoing and recently updated, and investors can track further protocol changes and results as they become available on the ClinicalTrials.gov portal.
To learn more about ENLV’s potential, visit the Enlivex Therapeutics drug pipeline page.